1-{4-Hydroxy-5-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-pentyl}-piperidin-2-one | 223254-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-{4-Hydroxy-5-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-pentyl}-piperidin-2-one
• 英文别名: 1-[4-hydroxy-2-oxo-5-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]pentyl]piperidin-2-one
• CAS: 223254-30-6
• 化学式: C₂₃H₃₅N₃O₄
• 分子量: 417.549
• InChiKey: UTACGRWSJNDCLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  73.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-{4-Hydroxy-5-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-pentyl}-piperidin-2-one 在 4-二甲氨基吡啶 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-[2-oxo-5-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]pent-3-enyl]piperidin-2-one
  参考文献：
  名称：

  Heterocycles useful in the treatment of benign prostatic hyperplasia

  摘要：

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。

  公开号：

  US06384035B1
• 作为产物：
  描述：

  2-(1-methylethoxy)phenyl-1-piperazine 在 草酰氯 、 potassium carbonate 、 二甲基亚砜 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 0.5h， 生成 1-{4-Hydroxy-5-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-pentyl}-piperidin-2-one
  参考文献：
  名称：

  Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists

  摘要：

  A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00169-4

文献信息

• Heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06384035B1

  公开（公告）日：2002-05-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。
• Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists
  作者：Xiaobing Li、William V Murray、Linda Jolliffe、Virginia Pulito

  DOI：10.1016/s0960-894x(00)00169-4

  日期：2000.5

  A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.